ACHE and Alzheimer disease: Notably, the study’s findings revealed that EGCG is a poor inhibitor of AChE within a range of 10 to 300 mg/kg; however, EGCG addition substantially enhanced the inhibitory effects of huperzine A on AChE activity in AD, which might be attributed to EGCG’s antioxidant action [119].